CRWF Partners with Fengate for Expansion
News related to:Clinical Research of West Florida · 2 min read
LOS ANGELES, Oct. 16, 2026 /CourierPR/ -- Clinical Research of West Florida, a leading independent clinical research platform operating three Phase I, IV facilities across the Tampa Bay area, has entered a significant partnership with Fengate Private Equity, a division of Fengate Asset Management. The partnership, facilitated by Westcove Partners, LLC, a highly specialized investment bank, marks a pivotal moment for CRWF as it looks to expand its operations and capabilities in new markets and therapeutic areas.
Founded in 1995, CRWF has conducted over 1,000 clinical trials across a broad range of therapeutic areas, with a particular focus on complex autoimmune and rheumatology indications. The company's experienced investigator base, proprietary patient database, and preferred relationships with leading sponsors and CROs have established it as a trusted partner for high-quality trial execution and patient enrollment.
Fengate Private Equity, a division of Fengate Asset Management, is a leading alternative investment manager with more than $20 billion in assets under management. The firm leverages over 50 years of entrepreneurial experience to deliver excellent investment results on behalf of its clients. Fengate Private Equity's involvement in this partnership underscores its commitment to supporting the growth ambitions of entrepreneurs through transformative capital.
Westcove Partners, LLC, a premier healthcare-focused investment bank, provided exclusive financial advisory services to CRWF in this transaction. The terms of the transaction were not disclosed.
CRWF's three Phase I, IV facilities are strategically located in the Bay area, serving the Tampa Bay region for over 30 years. The company's expertise in conducting clinical trials across a diverse range of therapeutic areas, with a particular focus on complex autoimmune and rheumatology indications, has solidified its position as a trusted partner for pharmaceutical sponsors and CROs.
The partnership with Fengate Private Equity represents a significant step forward for CRWF, allowing the company to expand its operations and capabilities in new markets and therapeutic areas. With the support of Westcove Partners and Fengate Private Equity, CRWF is poised to continue its legacy of excellence in the clinical research industry.